Single User License
INR 129000
Site License
INR 258000
Corporate User License
INR 387000

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Celiac Disease-Pipeline Review, H1 2017

Celiac Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9177IDB
  • |
  • Pages: 82
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Celiac Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease-Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Celiac Disease-Overview 6

Celiac Disease-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Celiac Disease-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Celiac Disease-Companies Involved in Therapeutics Development 23

Amgen Inc 23

Amyra Biotech AG 23

Calypso Biotech SA 24

Circle33 LLC 24

enGene Inc 25

F. Hoffmann-La Roche Ltd 25

Glenmark Pharmaceuticals Ltd 26

ImmusanT Inc 26

Innovate Biopharmaceuticals Inc 27

Intrexon Corp 27

Sanofi 28

Takeda Pharmaceutical Company Ltd 28

Zedira GmbH 29

Celiac Disease-Drug Profiles 30

AMG-714-Drug Profile 30

AVX-176-Drug Profile 32

Biologic for Celiac Disease-Drug Profile 33

BNZ-2-Drug Profile 34

CALY-002-Drug Profile 35

ERW-1041E-Drug Profile 36

GBR-830-Drug Profile 37

Kuma-010-Drug Profile 38

larazotide acetate-Drug Profile 39

latiglutenase-Drug Profile 42

Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology-Drug Profile 45

Nexvax-2-Drug Profile 46

Nexvax-3-Drug Profile 49

Oligonucleotides for Celiac Disease-Drug Profile 50

Protein for Celiac Disease-Drug Profile 51

Recombinant Enzymes to Inhibit Gluten for Celiac Disease-Drug Profile 52

Recombinant Protein for Celiac Disease-Drug Profile 53

RG-7625-Drug Profile 54

Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes-Drug Profile 55

Vaccine for Celiac Disease-Drug Profile 56

Vaccine for Celiac Disease-Drug Profile 58

vedolizumab-Drug Profile 59

ZED-1227-Drug Profile 66

ZED-754-Drug Profile 67

Celiac Disease-Dormant Projects 68

Celiac Disease-Product Development Milestones 69

Featured News & Press Releases 69

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Figures

Number of Products under Development for Celiac Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Celiac Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Celiac Disease-Pipeline by Amgen Inc, H1 2017

Celiac Disease-Pipeline by Amyra Biotech AG, H1 2017

Celiac Disease-Pipeline by Calypso Biotech SA, H1 2017

Celiac Disease-Pipeline by Circle33 LLC, H1 2017

Celiac Disease-Pipeline by enGene Inc, H1 2017

Celiac Disease-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Celiac Disease-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Celiac Disease-Pipeline by ImmusanT Inc, H1 2017

Celiac Disease-Pipeline by Innovate Biopharmaceuticals Inc, H1 2017

Celiac Disease-Pipeline by Intrexon Corp, H1 2017

Celiac Disease-Pipeline by Sanofi, H1 2017

Celiac Disease-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Celiac Disease-Pipeline by Zedira GmbH, H1 2017

Celiac Disease-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc, Amyra Biotech AG, Calypso Biotech SA, Circle33 LLC, enGene Inc, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp, Sanofi, Takeda Pharmaceutical Company Ltd, Zedira GmbH


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com